GlassScriptPhysician profile
Andrew James Buresh
NPI 1902870959
$2,058.87
in general payments reported to CMS, 2019-2025
32 companies · $18.90 in 2025
The $18.90 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $66.99 · 2021: $30.52 · 2022: $35.59 · 2023: $65.97 · 2024: $17.49 · 2025: $18.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.36 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.36 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $279.56 | 2019-2025 | Erleada |
| Merck Sharp & Dohme LLC | $245.95 | 2019 | |
| Genentech USA, INC. | $150.43 | 2019 | |
| Genzyme Corporation | $123.45 | 2019 | |
| Pfizer INC. | $112.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $110.80 | 2019 | |
| Seagen INC. | $92.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $86.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $78.68 | 2019 | |
| Amgen INC. | $77.98 | 2019 | |
| Exelixis INC. | $74.19 | 2019 | |
| Puma Biotechnology, INC. | $48.42 | 2019 | |
| Daiichi Sankyo INC. | $46.13 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $42.81 | 2019 | |
| Sun Pharmaceutical Industries INC. | $38.57 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $29.58 | 2019 | |
| Telix Pharmaceuticals | $28.45 | 2023 | Illuccix |
| Takeda Pharmaceuticals U.S.A., INC. | $23.82 | 2019 | |
| Tesaro, INC. | $22.80 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Lexicon Pharmaceuticals, INC. | $18.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2019 | |
| Boston Scientific Corporation | $18.60 | 2021 | |
| Spectrum Pharmaceuticals INC. | $17.11 | 2019 | |
| Kite Pharma, INC. | $16.52 | 2023 | Yescarta |
| Abbvie INC. | $15.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.26 | 2019 | |
| Lilly USA, LLC | $13.61 | 2019 | |
| Verastem, INC. | $12.36 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Buresh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.